Lengyel E - Search Results

1

Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.

Schmalfeldt B, Prechtel D, Härting K, Späthe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W, Lengyel E. Schmalfeldt B, et al. Among authors: lengyel e. Clin Cancer Res. 2001 Aug;7(8):2396-404. Clin Cancer Res. 2001. PMID: 11489818

2

Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer.

Schaller G, Fuchs I, Pritze W, Ebert A, Herbst H, Pantel K, Weitzel H, Lengyel E. Schaller G, et al. Among authors: lengyel e. Clin Cancer Res. 1996 Nov;2(11):1879-85. Clin Cancer Res. 1996. PMID: 9816144

3

Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor.

Ried S, Jäger C, Jeffers M, Vande Woude GF, Graeff H, Schmitt M, Lengyel E. Ried S, et al. Among authors: lengyel e. J Biol Chem. 1999 Jun 4;274(23):16377-86. doi: 10.1074/jbc.274.23.16377. J Biol Chem. 1999. PMID: 10347197 Free article.

4

UVB increases urokinase-type plasminogen activator receptor (uPAR) expression.

Marschall C, Lengyel E, Nobutoh T, Braungart E, Douwes K, Simon A, Magdolen V, Reuning U, Degitz K. Marschall C, et al. Among authors: lengyel e. J Invest Dermatol. 1999 Jul;113(1):69-76. doi: 10.1046/j.1523-1747.1999.00631.x. J Invest Dermatol. 1999. PMID: 10417621 Free article.

5

Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b.

Schnelzer A, Prechtel D, Knaus U, Dehne K, Gerhard M, Graeff H, Harbeck N, Schmitt M, Lengyel E. Schnelzer A, et al. Among authors: lengyel e. Oncogene. 2000 Jun 15;19(26):3013-20. doi: 10.1038/sj.onc.1203621. Oncogene. 2000. PMID: 10871853 Free article.

6

Downregulation of a mitogen-activated protein kinase signaling pathway in the placentas of women with preeclampsia.

Hannke-Lohmann A, Pildner von Steinburg S, Dehne K, Benard V, Kolben M, Schmitt M, Lengyel E. Hannke-Lohmann A, et al. Among authors: lengyel e. Obstet Gynecol. 2000 Oct;96(4):582-7. doi: 10.1016/s0029-7844(00)00986-8. Obstet Gynecol. 2000. PMID: 11004363

7

beta(3)A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter.

Hapke S, Gawaz M, Dehne K, Köhler J, Marshall JF, Graeff H, Schmitt M, Reuning U, Lengyel E. Hapke S, et al. Among authors: lengyel e. Mol Cell Biol. 2001 Mar;21(6):2118-32. doi: 10.1128/MCB.21.6.2118-2132.2001. Mol Cell Biol. 2001. PMID: 11238946 Free PMC article.

8

Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells.

Hapke S, Kessler H, Arroyo de Prada N, Benge A, Schmitt M, Lengyel E, Reuning U. Hapke S, et al. Among authors: lengyel e. J Biol Chem. 2001 Jul 13;276(28):26340-8. doi: 10.1074/jbc.M100181200. Epub 2001 Apr 30. J Biol Chem. 2001. PMID: 11331280 Free article.

9

Ras regulation of urokinase-type plasminogen activator.

Lengyel E, Ried S, Heiss MM, Jäger C, Schmitt M, Allgayer H. Lengyel E, et al. Methods Enzymol. 2001;333:105-16. doi: 10.1016/s0076-6879(01)33049-5. Methods Enzymol. 2001. PMID: 11400328 Review. No abstract available.

10

Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.

Lengyel E, Schmalfeldt B, Konik E, Späthe K, Härting K, Fenn A, Berger U, Fridman R, Schmitt M, Prechtel D, Kuhn W. Lengyel E, et al. Gynecol Oncol. 2001 Aug;82(2):291-8. doi: 10.1006/gyno.2001.6243. Gynecol Oncol. 2001. PMID: 11531282

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

265 results

Search Page

Filters